Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,800
+440 (3.06%)
Last updated: Aug 28, 2026, 2:28 PM KST

Ildong Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
582,335566,934614,941600,758637,714560,132
Other Revenue
0---0--0
582,335566,934614,941600,758637,714560,132
Revenue Growth
-0.65%-7.81%2.36%-5.79%13.85%-0.30%
Cost of Revenue
351,801347,353381,659387,093401,627340,958
Gross Profit
230,534219,581233,282213,665236,088219,174
Selling, General & Admin
160,873157,965167,539165,116190,252171,296
Research & Development
38,13135,59946,26895,018109,89596,524
Other Operating Expenses
1,1651,3041,2621,2163,8141,087
Operating Expenses
204,995202,258221,851267,082309,754273,586
Operating Income
25,53917,32211,431-53,418-73,666-54,412
Interest Expense
-8,326-12,173-15,938-14,725-9,788-10,556
Interest & Investment Income
616.21942.071,1261,0931,552569.37
Earnings From Equity Investments
761.36283.69-273.49-0.36-0.54-1.67
Currency Exchange Gain (Loss)
-356.66-47.26-1,016-748.46-475.09168.49
Other Non Operating Income (Expenses)
20,04122,4316,790-24,556-20,485-75,458
EBT Excluding Unusual Items
38,27528,7592,119-92,354-102,862-139,690
Gain (Loss) on Sale of Investments
9,4597,6431,955439.722,325-862.82
Gain (Loss) on Sale of Assets
-908.09-2,146-4,9081,133-282.22-101.53
Asset Writedown
--2,536-9,857-3,492-19,004-550.27
Other Unusual Items
229.0733.33----
Pretax Income
47,05531,753-10,692-94,273-119,823-141,205
Income Tax Expense
7,4848,0551,710-13,31222,346-40,237
Earnings From Continuing Operations
39,57223,698-12,402-80,961-142,170-100,968
Minority Interest in Earnings
4,0373,9677,8252,033584.61,263
Net Income
43,60927,664-4,576-78,928-141,585-99,705
Net Income to Common
43,60927,664-4,576-78,928-141,585-99,705
Net Income Growth
------
Shares Outstanding (Basic)
312928272624
Shares Outstanding (Diluted)
333128272624
Shares Change
16.74%10.01%3.34%2.61%10.76%-0.00%
EPS (Basic)
1397.67942.08-163.83-2920.01-5374.53-4191.88
EPS (Diluted)
1373.58936.77-164.00-2920.01-5379.82-4192.00
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
22,4305,30417,614-49,817-65,413-25,992
Free Cash Flow Per Share
688.80172.61630.60-1843.01-2483.08-1092.76
Dividend Per Share
200.000200.000----
Dividend Growth
------
Gross Margin
39.59%38.73%37.94%35.57%37.02%39.13%
Operating Margin
4.39%3.06%1.86%-8.89%-11.55%-9.71%
Profit Margin
7.49%4.88%-0.74%-13.14%-22.20%-17.80%
Free Cash Flow Margin
3.85%0.94%2.86%-8.29%-10.26%-4.64%
EBITDA
47,60839,89837,366-25,099-44,121-25,101
EBITDA Margin
8.18%7.04%6.08%-4.18%-6.92%-4.48%
D&A For EBITDA
22,06922,57625,93528,31929,54529,311
EBIT
25,53917,32211,431-53,418-73,666-54,412
EBIT Margin
4.39%3.06%1.86%-8.89%-11.55%-9.71%
Effective Tax Rate
15.90%25.37%----
Advertising Expenses
-27,42632,05325,84637,39235,757